U.S. Markets close in 4 hrs 31 mins

These 4 Pharma Stocks Could Test December Highs

CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The pharmaceutical industry is predicated on the notion that treatments for various ailments can always be improved upon, and patients suffering from these diseases both demand and need better treatment options. As pharmaceutical companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety may benefit from these efforts. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals, Inc (SGYP), Pieris Pharmaceuticals, Inc (PIRS), and Obalon Therapeutics Inc (OBLN) are 4 pharma stocks representing companies invested in creating the best quality drug treatments for their patients.

Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.66 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from several weeks ago on December 9. On Monday, the Company announced that, as a means of furthering their efforts to develop innovative approaches that combine human-skill based expertise with emerging technologies for the healthcare industry, it had signed a binding letter of intent to acquire all outstanding securities of Cloud Practice Inc.

In affirmation of the LOI, Premier's CEO, Dr. Essam Hamza, said:

''We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system.''

For More Information On Premier Health Group, Click Here

Synergy Pharmaceuticals, Inc (SGYP), a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced last week that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.

"We have worked diligently to serve our patients, health care professionals and other stakeholders by bringing TRULANCE® to market and developing other GI therapies to address previously unmet needs. Unfortunately, we have now reached a point where our financial challenges are preventing us from taking this important work to the next level," said Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc. ''We are confident that this process will result in a strong new owner that has the necessary funding and commercialization capabilities to continue providing TRULANCE to the patients and providers who have come to rely on this treatment and will allow us to maximize value for all stakeholders.''

For More Information On Synergy Pharmaceuticals, Inc, Click Here

Pieris Pharmaceuticals, Inc (PIRS), like other clinical-stage biotechnology company in the industry, is invested in advancing biotherapeutics through its proprietary Anticalin® technology platform for treating respiratory cancer and other diseases. In early November, the Company reported its quarter earnings for the third quarter of 2018, and announced several corporate updates.

Per the press release issued at the time: ''We are pleased to announce that PRS-060, an IL-4 receptor alpha antagonist for moderate-to-severe asthma, was safe and well-tolerated by healthy volunteers in a single ascending dose Phase I study. This is the first clinical use of an inhaled Anticalin protein and marks an important development milestone for the Company. We continue to enroll subjects with mild asthma in a multiple ascending dose Phase I study."

For More Information on Pieris Pharmaceuticals, Inc, Click Here

Obalon Therapeutics, Inc (OBLN) opened Friday with an astounding 43% increase in their share price, trading at $2.36 per share just before the afternoon. The Company's performance may have to do with the fact that they announced that they received approval from the U.S. Food and Drug Administration of the Obalon Navigation System, which eliminates the need to use x-ray when placing the Obalon Balloon System.

''We're very pleased about the approval of the Obalon Navigation System which is intended to make placement of the Obalon Balloon more reliable, more convenient and more accessible to physician providers and patients by eliminating the costs and logistics related to acquiring x-ray,'' commented Kelly Huang, Ph.D., President and Chief Operating Officer of Obalon. ''I'd like to recognize the FDA for their timely review of the Obalon Navigation System, as well as the Touch Inflation Dispenser which was previously approved in the third quarter of 2018. We believe Navigation and Touch provide another step forward in helping physicians and patients battle the obesity epidemic.''

For More Information On Obalon Therapeutics, Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 -4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ''500,000'' shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

CONTACT:

news@stockprice.com

SOURCE: Stock Price